VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Changes in Registrant’s Certifying Accountant
ITEM 4.01CHANGES IN REGISTRANT’S INDEPENDENT REGISTERED PUBLIC
ACCOUNTANT
Effective December 6, 2018, the Company’s independent registered public accountants Schumacher & Associates, Inc. (“Schumacher”) informed the Company that they resigned as the Company’s independent registered public accountants. In the period from Schumacher & Associates, Inc.’s appointment in 2007 until December 6, 2018 (the date of resignation), there were no disagreements with Schumacher & Associates, Inc. on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of Schumacher & Associates, Inc., would have caused Schumacher & Associates, Inc. to make reference to the matter in its report on the Company’s financial statements; and there were no reportable events as defined in Item 304(a) (1) of Regulation S-K. Schumacher & Associates, Inc., issued audit reports on our financial statements as of and for the years ended October 31, 2006 through 2015 which reports each included an explanatory paragraph concerning the Company’s ability to continue as a going concern.
As of the date of this Report, the Company has not appointed a successor independent registered public accountant.
The Company has provided Schumacher & Associates, Inc. with a copy of the above disclosures. Attached as Exhibit 16 is a copy of Schumacher & Associates, Inc.’s letter, dated December 7, 2018, stating its agreement with such statements.
Item 9.01 Financial Statements and Exhibits
|
(a) |
Financial statements of businesses acquired. |
Not applicable
|
(b) |
Pro forma financial information. |
Not applicable
(c)Shell company transactions.
Not applicable
VITRO DIAGNOSTICS INC Exhibit
EX-16 2 vitro_16ez0.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM SCHUMACHER & ASSOCIATES,…
To view the full exhibit click here
About VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG)
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.
